Sensei Biotherapeutics: A Strategic Crossroads After Clinical Halt

Following the termination of its lead candidate’s development, Sensei Biotherapeutics is navigating a comprehensive strategic review. The company’s leadership is evaluating a spectrum of potential outcomes, including asset divestitures, licensing agreements, strategic partnerships, an outright sale, a merger, or an orderly wind-down of operations. This analysis delves into the remaining options and the financial runway available to execute them.

The company’s cash reserves stood at $25.0 million as of September 30, 2025, a decrease from the $41.3 million reported at the end of 2024. This burn rate reflects the company’s operational scale-back. For the third quarter of 2025, research and development expenses were $2.5 million, down from $4.6 million in the prior-year period. General and Read more...